Skip to main content
Smart Investors Daily
TC

NASDAQ · TCDA

Tricida, Inc.

Healthcare · Biotechnology

$0.11

Up+$0.00 (+0.00%)

Updated Aug 15, 2026, 4:58 AM

SID Score

Composite research score

Smart Money

Institutional and insider signal

Market cap
5.95M
P/E ratio
-0.03
Dividend yield
0.00%
52-week range
— – —
Volume
31.13M
Avg. volume
11.43M

Price performance

TCDA price history

1M range · 0 trading sessions · Daily adjusted prices

TCDA does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest TCDA news

The latest Smart Investors Daily articles mentioning TCDA.

TCDA research

Overview

Company profile and research snapshot.

Company profile

Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Average target
$16.00
Implied upside
Analysts
TCDA recent ratings
DateFirmRatingTarget
Oct 25, 2022NeedhamHold
Oct 25, 2022JP MorganUnderweight
Oct 24, 2022Cowen & Co.Market Perform
May 24, 2022Goldman SachsBuy
May 11, 2022Goldman SachsBuy
Open full forecast

News briefing

No generated briefing is available yet.

Benzinga · Jan 19, 2023

Why Starbox Group Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket

Gainers Tricida, Inc. (NASDAQ: TCDA) rose 37.7% to $0.1898 in pre-market trading after gaining 4% on Wednesday. Huadi International Group Co., Ltd. (NASDAQ: HUDI) rose 26.7% to $7.16 in pre-market trading after gaining over 3% on Wednesday. Starbox Group Holdings Ltd. (NASDAQ: STBX) shares rose 22.1% to $3.65 in pre-market trading after the company reported a rise in FY22 earnings. AIM ImmunoTech Inc. (NYSE: AIM) shares rose 15.8% to $0.73 in pre-market trading after dropping 18% on Wednesday. AIM ImmunoTech recently entered into a sponsored collaborative clinical research agreement with Erasmus MC and AstraZeneca. Zymeworks Inc. (NASDAQ: ZYME) rose 12% to $11.20 in pre-market trading. Berkshire Grey, Inc. (NASDAQ: BGRY) shares rose 11.3% to $0.97 in pre-market trading after dropping 14% on Wednesday. TransCode Therapeutics, Inc. (NASDAQ: RNAZ) rose 11% to $0.7680 in pre-market trading after jumping 15% on Wednesday. TransCode Therapeutics recently announced it received written authorization from the FDA that ...

Benzinga · Jan 13, 2023

5 Cheapest Health Care Stocks You Should Think About

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30. Here’s the latest list of major oversold players in this sector, having an RSI near or below 30. Tricida, Inc. (NASDAQ: TCDA) The company’s stock dropped around 98% over the past six months. The company’s stock has a 52-week low of $0.13 . RSI ...

PennyStocks · Dec 7, 2022

10 Top Penny Stocks To Watch Under $1 This Week

Penny stocks under $1 to watch this week. The post 10 Top Penny Stocks To Watch Under $1 This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

PennyStocks · Nov 27, 2022

What Penny Stocks Industries Are Popular Right Now?

These industries could be worth looking into to find penny stocks to watch The post What Penny Stocks Industries Are Popular Right Now? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.